- Home
- JFBR vs DRMA Comparison
JFBR vs DRMA Comparison
Compare JFBR & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFBR
- DRMA
- Stock Information
- Founded
- JFBR 2017
- DRMA 2014
- Country
- JFBR Israel
- DRMA United States
- Employees
- JFBR N/A
- DRMA N/A
- Industry
- JFBR Other Specialty Stores
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- JFBR Consumer Discretionary
- DRMA Health Care
- Exchange
- JFBR Nasdaq
- DRMA Nasdaq
- Market Cap
- JFBR 3.6M
- DRMA 3.3M
- IPO Year
- JFBR 2022
- DRMA 2021
- Fundamental
- Price
- JFBR $4.21
- DRMA $4.31
- Analyst Decision
- JFBR
- DRMA Strong Buy
- Analyst Count
- JFBR 0
- DRMA 1
- Target Price
- JFBR N/A
- DRMA $10.00
- AVG Volume (30 Days)
- JFBR 197.0K
- DRMA 256.5K
- Earning Date
- JFBR 09-22-2025
- DRMA 11-12-2025
- Dividend Yield
- JFBR N/A
- DRMA N/A
- EPS Growth
- JFBR N/A
- DRMA N/A
- EPS
- JFBR N/A
- DRMA N/A
- Revenue
- JFBR $14,474,000.00
- DRMA N/A
- Revenue This Year
- JFBR N/A
- DRMA N/A
- Revenue Next Year
- JFBR N/A
- DRMA N/A
- P/E Ratio
- JFBR N/A
- DRMA N/A
- Revenue Growth
- JFBR 17.34
- DRMA N/A
- 52 Week Low
- JFBR $3.40
- DRMA $4.22
- 52 Week High
- JFBR $90.30
- DRMA $23.70
- Technical
- Relative Strength Index (RSI)
- JFBR 46.61
- DRMA 39.01
- Support Level
- JFBR $4.06
- DRMA $4.56
- Resistance Level
- JFBR $4.54
- DRMA $5.87
- Average True Range (ATR)
- JFBR 0.40
- DRMA 0.43
- MACD
- JFBR 0.05
- DRMA -0.08
- Stochastic Oscillator
- JFBR 28.76
- DRMA 4.88
About JFBR Jeffs' Brands Ltd
Jeffs Brands Ltd is an e-commerce CPG company, operating on Amazon. The company serves as the holding company of other e-commerce companies, Smart Repair Pro, Purex, and Top Rank, that operate online stores for the sale of various consumer products on Amazon online marketplace, utilizing the FBA model. The company has five wholly-owned subsidiaries: Smart Repair Pro, Purex, Top Rank, Fort and Jeffs' Brands Holdings. The company also utilizes internal methodologies to analyze sales data and patterns on Amazon to identify existing stores, niches, and products that have the potential for development and growth, and for maximizing sales of existing proprietary products.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.